Overview
Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by the accumulation of surfactant-related material in the alveoli, leading to respiratory symptoms such as dyspnea and hypoxemia 2.Diagnosis
Imaging: High-resolution computed tomography (HRCT) showing characteristic reticular opacities and ground-glass opacities 2.
Bronchoalveolar Lavage (BAL): Demonstrates milky fluid with foamy macrophages 2.
Serology: Evaluation of GM-CSF antibodies; genetic testing for specific mutations (e.g., METRS) 23.
Lung Biopsy: Reserved for cases where diagnosis remains unclear 2.Management
First-line Treatment:
- Whole Lung Lavage (WLL): Standard treatment for significant symptom relief 12.
Adjunctive Treatments:
- GM-CSF Therapy: Augmentation therapy for patients who are not candidates for WLL 2.
- Rituximab: Considered in refractory cases or those with GM-CSF antibodies 2.
- Methionine Supplementation: Beneficial in METRS-related PAP, showing respiratory improvement and reduced need for WLL 3.
Advanced Options:
- Lung Transplantation: For end-stage disease unresponsive to other treatments 2.Special Populations
Pediatrics: Methionine supplementation shows promise in improving respiratory and multi-organ dysfunction in children with METRS-related PAP 3.
Comorbidities: Management strategies may need adjustment in patients with severe hypoxemia, potentially requiring ECMO support during WLL 1.Key Recommendations
Primary Diagnostic Approach: Utilize HRCT, BAL, and GM-CSF antibody testing for diagnosis (Evidence: Strong 2).
Mainstay Treatment: Whole lung lavage is recommended for symptomatic patients with significant disease burden (Evidence: Strong 12).
Consider GM-CSF Therapy: For patients unsuitable for WLL, consider GM-CSF augmentation therapy (Evidence: Moderate 2).
Methionine Supplementation: In cases of METRS-related PAP, consider methionine supplementation for respiratory and multi-organ improvement (Evidence: Moderate 3).
Advanced Support: Employ ECMO for severe hypoxemia complications during WLL procedures (Evidence: Expert opinion 1).References
1 Sikachi R, Anders M. Whole lung lavage: considerations from the anesthesiology perspective. Current opinion in pulmonary medicine 2025. link
2 McCarthy C, Bonella F, O'Callaghan M, Dupin C, Alfaro T, Fally M et al.. European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis. The European respiratory journal 2024. link
3 Hadchouel A, Drummond D, Pontoizeau C, Aoust L, Hurtado Nedelec MM, El Benna J et al.. Methionine supplementation for multi-organ dysfunction in MetRS-related pulmonary alveolar proteinosis. The European respiratory journal 2022. link
4 Deacu M, Tofolean DE, Boşoteanu M, Aşchie M, Bulbuc I. Pulmonary alveolar lipoproteinosis associated with emphysematous areas. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2012. link
5 Doyle IR, Davidson KG, Barr HA, Nicholas TE, Payne K, Pfitzner J. Quantity and structure of surfactant proteins vary among patients with alveolar proteinosis. American journal of respiratory and critical care medicine 1998. link
6 Arora VK, Seetharaman ML, Veliath AJ. Silicotic alveolar proteinosis with bilateral spontaneous pneumothorax. The Journal of the Association of Physicians of India 1992. link